Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Oct 8;27(1):198.
doi: 10.1186/s40001-022-00835-4.

Tumor microenvironment and immunotherapy of oral cancer

Chang Liu  1 , Min Wang  1 , Haiyang Zhang  1 , Chunyan Li  1 , Tianshou Zhang  1 , Hong Liu  1 , Song Zhu  2 , Jie Chen  3
Affiliations
Review

Tumor microenvironment and immunotherapy of oral cancer

Chang Liu et al. Eur J Med Res. .

Abstract

Oral cancer is one of the most common malignant tumors of the head and neck, not only affects the appearance, but also affects eating and even endangers life. The clinical treatments of oral cancer mainly include surgery, radiotherapy, and chemotherapy. However, unsatisfactory therapeutic effect and toxic side effects are still the main problems in clinical treatment. Tumor microenvironment (TME) is not only closely related to the occurrence, growth, and metastasis of tumor but also works in the diagnosis, prevention, and treatment of tumor and prognosis. Future studies should continue to investigate the relationship of TME and oral cancer therapy. This purpose of this review was to analyze the characteristics of oral cancer microenvironment, summarize the traditional oral cancer therapy and immunotherapy strategies, and finally prospect the development prospects of oral cancer immunotherapy. Immunotherapy targeting tumor microenvironment is expected to provide a new strategy for clinical treatment of oral cancer.

Keywords: Immune checkpoint blockade; Immune tolerance; Immunotherapy; Oral cancer; Tumor microenvironment.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
Schematic diagram of the microenvironment of oral cancer
Fig. 2
Fig. 2
Immunotherapy strategies for oral caners
Fig. 3
Fig. 3
Schematic diagram of CAR-T therapy
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Bagan J, Sarrion G, Jimenez Y. Oral cancer: clinical features. Oral Oncol. 2010;46:414–417. doi: 10.1016/j.oraloncology.2010.03.009. - DOI - PubMed
    1. Rhodus NL, Kerr AR, Patel K. Oral cancer: leukoplakia, premalignancy, and squamous cell carcinoma. Dent Clin North Am. 2014;58:315–340. doi: 10.1016/j.cden.2013.12.004. - DOI - PubMed
    1. Speight PM, Farthing PM. The pathology of oral cancer. Br Dent J. 2018;225:841–847. doi: 10.1038/sj.bdj.2018.926. - DOI - PubMed
    1. Mignogna MD, Fedele S, Lo Russo L. The world cancer report and the burden of oral cancer. Eur J Cancer Prev. 2004;13:139–142. doi: 10.1097/00008469-200404000-00008. - DOI - PubMed
    1. De Virgilio A, Costantino A, Mercante G, et al. Present and future of de-intensification strategies in the treatment of oropharyngeal carcinoma. Curr Oncol Rep. 2020 doi: 10.1007/s11912-020-00948-1. - DOI - PubMed